Literature DB >> 25130242

Injectable Contraceptive Continuation among Female Exotic Dancers Seeking Mobile Reproductive Health Services.

Caitlin E Martin, Jennifer J Han, Chris Serio-Chapman, Patrick Chaulk, Mishka Terplan.   

Abstract

OBJECTIVES: We describe depot medroxyprogesterone acetate (DMPA) continuation patterns among female exotic dancers receiving reproductive health services at a mobile syringe exchange.
METHODS: Clients initiating DMPA between November 2009 and August 2012 were identified retrospectively via chart review. Life table analysis measured continuation. Client characteristics were compared using chi-square tests.
RESULTS: Sixty nine clients were identified; 72% were African American and 63% were younger than 25. At three months, 36% of the study sample continued DMPA; those continuing were more likely to be White (p=0.01) and receive other services (p=.01). The 12-month cumulative continuation probability was 0.09. Considering those who had received an injection, continuation proportions were higher (46% at 6; 71% at 12 months).
CONCLUSIONS: A subset of female exotic dancers may favor DMPA as a long term contraceptive. Integrating mobile reproductive health services into public health programs can help fulfill the unique health needs of this high-risk population.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25130242     DOI: 10.1353/hpu.2014.0134

Source DB:  PubMed          Journal:  J Health Care Poor Underserved        ISSN: 1049-2089


  2 in total

1.  Innovative approaches to reduce unintended pregnancy and improve access to contraception among women who use opioids.

Authors:  Sarah H Heil; Heidi S Melbostad; Catalina N Rey
Journal:  Prev Med       Date:  2019-08-06       Impact factor: 4.018

2.  Expanding Contraception Access for Women With Opioid-Use Disorder: A Qualitative Study of Opportunities and Challenges.

Authors:  Emily A Hurley; Alex Duello; Sarah Finocchario-Kessler; Kathy Goggin; Stephani Stancil; Rachel P Winograd; Melissa K Miller
Journal:  Am J Health Promot       Date:  2020-05-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.